Fairvalue-Calculator Fairvalue-Calculator
EN DE

DreamCIS, Inc (223250) Fair Value & Analysis

Healthcare · KR · Market cap 93.4B KRW

Price3,375 KRW
Fair Value5,682 KRW
Upside+68.4%
Quality87/100
Evidence: Medium Range 4,496 KRW – 6,868 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

DreamCIS, Inc (223250) currently trades at 3,375 KRW, while our model-based Fair Value estimate is 5,682 KRW — implying the stock looks roughly 68.4% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd.

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) -74% Fresenius SE (FSNUY) -25% 5225 (5225) -64% IHHHF (IHHHF) -57% Rede D'Or São Luiz S.A (RDOR3) +42% Tenet Healthcare Corporation (THC) +70%

Frequently asked questions

Is DreamCIS, Inc (223250) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5,682 KRW versus a price of 3,375 KRW — about +68% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 223250?
Our 21-model fair value for DreamCIS, Inc is 5,682 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,375 KRW.
What is the quality score of 223250?
DreamCIS, Inc has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.